Isaac Cheng - 06 Jan 2022 Form 4 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role
Director
Signature
/s/ Joshua B. Cohen, as Attorney-in-Fact
Issuer symbol
AMLX
Transactions as of
06 Jan 2022
Transactions value $
$124,982
Form type
4
Filing time
10 Jan 2022, 19:35:56 UTC
Next filing
10 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMLX Common Stock Conversion of derivative security +1.41M 1.41M 06 Jan 2022 See Footnote F1, F2
transaction AMLX Common Stock Conversion of derivative security +6.41M +454.99% 7.82M 06 Jan 2022 See Footnote F1, F2
transaction AMLX Common Stock Conversion of derivative security +974K +12.46% 8.79M 06 Jan 2022 See Footnote F1, F2
transaction AMLX Common Stock Conversion of derivative security +1.62M +18.44% 10.4M 06 Jan 2022 See Footnote F1, F2
transaction AMLX Common Stock Purchase $125K +6.58K $19.00 6.58K 06 Jan 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMLX Series A Preferred Stock Conversion of derivative security $0 -1.41M -100% $0.00* 0 06 Jan 2022 Common Stock 1.41M See Footnote F1, F2
transaction AMLX Series B Preferred Stock Conversion of derivative security $0 -6.41M -100% $0.00* 0 06 Jan 2022 Common Stock 6.41M See Footnote F1, F2
transaction AMLX Series C-1 Preferred Stock Conversion of derivative security $0 -974K -100% $0.00* 0 06 Jan 2022 Common Stock 974K See Footnote F1, F2
transaction AMLX Series C-2 Preferred Stock Conversion of derivative security $0 -1.62M -100% $0.00* 0 06 Jan 2022 Common Stock 1.62M See Footnote F1, F2
transaction AMLX Stock Option (Right to Buy) Award $0 +8.4K $0.00 8.4K 06 Jan 2022 Common Stock 8.4K $19.00 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Upon the closing of the Issuer's initial public offering, all shares of Series A , Series B, Series C-1 and Series C-2 Preferred Stock will convert into the number of shares of Common Stock of the Issuer and have no expiration date.
F2 These shares are held directly by Morningside Venture Investments Limited, or Morningside, and MVIL, LLC, a wholly-owned subsidiary of Morningside. The Reporting Person is an investment professional at Morningside Technology Advisory, LLC, an indirect advisor to Morningside and MVIL, LLC and may be deemed to indirectly beneficially own the shares held by Morningside and MVIL, LLC. The Reporting Person has no voting or dispositive power over the shares held by the Morningside shareholder entities and therefore disclaims beneficial ownership of such shares.
F3 This option shall vest in full on the date of the Corporation's 2022 Annual Stockholders Meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date.